CervoMed Q3 Net Loss Narrows as R&D Costs Fall
CervoMed reported a narrower third-quarter net loss as research and development costs declined following completion of its RewinD-LB trial.
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…